The A1AT and IL-6 genotypes by PCR-RFLP. The left panel shows the M, S and Z alleles of the A1AT genotypes. M: DNA marker; ZZ genotype (179 and 100 bp band); SZ genotype (179, 157, 121 and 100 bp bands); MM genotype (157 and 100 bp bands); SM genotype (157, 121 and 100 bp bands). The right panel shows the G and C alleles of the IL-6 genotypes. GC genotype (168, 119 and 49 bp); GG genotype (168 bp band); CC genotype (119 and 49 bp bands); M: DNA marker.
Table 1
The clinical characteristics and biochemical parameters of the control group, chronic hepatitis patients and cirrhotic patients.
| Parameters | Control (n = 100) | Chronic Hepatitis Patients (n= 85) | Cirrhotic Patients (n = 65) |
|---|---|---|---|
| Sexes | M: 45; F: 55 | M: 55; F: 30 | M: 35; F: 30 |
| Age (years ± SE) | 33.10 ± 1.83 | 38.88 ± 1.92 | 38.92 ± 2.36 |
| Serum ALT (IU/mL) | 30.00 ± 1.34 | 83.53 ± 16.03a | 110.00 ± 14.63a |
| Serum AST (IU/mL) | 30.20 ± 1.36 | 76.76 ± 11.07a | 172.92 ± 27.76a,b |
| Serum ALP (IU/mL) | 43.65 ± 1.69 | 113.71 ± 6.51a | 119.85 ± 9.49a |
| Total bilirubin (mg/dL) | 0.75 ± 0.045 | 0.92 ± 0.098 | 1.09 ± 0.14a |
| Direct bilirubin (mg/dL) | 0.15 ± 0.01 | 0.25 ± 0.06 | 0.28 ± 0.05 |
| Albumin (g/dL) | 3.85 ± 0.05 | 3.69 ± 0.05 | 3.21 ± 0.11a,b |
| Prothrombin time (seconds) | 11.19 ± 0.14 | 11.53 ± 0.19 | 13.46 ± 0.51a,b |
| AFP (ng/mL) | 5.86 ± 0.45 | 8.76 ± 0.55 | 27.38 ± 6.91a,b |
| Fibrosis score (1-6) | — | 1.94 ± 0.18 | 4.46 ± 0.14a |
M: males; F: females; SE: standard error; ALT: alanine transaminase; AST: aspartate transaminase; ALP: alkaline phosphate; AFP: α fetopreotein.
Table 2
The single nucleotide polymorphism pattern of the IL-6 gene in the control group, chronic hepatitis patients and cirrhotic patients.
Table 3
The single nucleotide polymorphism pattern of the A1TAT gene in the control group, chronic hepatitis patients and cirrhotic patients.
| Parameters | Control Group n (%) | Chronic Hepatitis Patients n (%) | Cirrhotic Patients n (%) |
|---|---|---|---|
| Genotypes: | |||
| MM | 85 (85.0) | 40 (47.0) | 35 (53.8)a |
| MS | 10 (10.0) | 30 (35.3) | 15 (23.1) |
| MZ | 5 (5.0) | 5 (5.9) | 0 (0.0) |
| ZZ | 0 (0.0) | 10 (11.8) | 0 (0.0) |
| SS | 0 (0.0 | 0 (0.0) | 15 (23.1) |
| Alleles: | |||
| M | 185 (92.5) | 115 (67.6) | 85 (56.4)a |
| S | 10 (5.0) | 30 (17.6) | 45 (34.6)a |
| Z | 5 (2.5) | 25 (14.7) | 0 (0.0) |
Table 4
The biochemical parameters within different IL-6 genotypes in the control group, chronic hepatitis patients and cirrhotic patients.
| Parameters | Genotypes | ||||
|---|---|---|---|---|---|
| Control Group | Chronic Hepatitis Patients | Cirrhotic Patients | |||
| GG | GG+GC | CC | GG | GC | |
| Serum ALT (IU/mL) | 30.00±1.34 | 80.75±7.09 | 128.10±52.91 | 102.63±17.87 | 121.80±26.81 |
| Serum AST (IU/mL) | 30.20±1.36 | 73.33±5.61 | 137.45±35.74 | 150.50±28.65 | 208.80±54.69 |
| Serum ALP (IU/mL) | 43.65±1.69 | 115.93±5.45 | 78.34±19.49 | 125.25±14.21 | 111.20±10.31 |
| Total bilirubin (mg/dL) | 0.75±0.045 | 0.92±0.06 | 0.90±0.32 | 1.09±0.17 | 1.00±0.28 |
| Direct bilirubin (mg/dL) | 0.15±0.01 | 0.26±0.02 | 0.20±0.19 | 0.29±0.07 | 0.26±0.09 |
| Albumin (g/dL) | 3.85±0.05 | 3.69±0.07 | 3.60±0.06 | 3.26±0.13 | 3.12±0.23 |
| Prothrombin time (seconds) | 11.19±0.14 | 11.50±0.15 | 12.10±0.58 | 14.00±0.63 | 12.60±0.81 |
| AFP (ng/mL) | 5.86±0.45 | 8.87±0.65 | 7.00±1.05 | 25.63±8.94 | 30.20±12.04 |
| Fibrosis score (1-6) | — | 1.93±0.23 | 2.00±0.32 | 4.50±0.19 | 4.40±0.24 |
SE: standard error; ALT: alanine transaminase; AST: aspartate transaminase; ALP: alkaline phosphate; AFP: α fetopreotein.
Table 5
The biochemical parameters within different A1AT genotypes in the control group, chronic hepatitis patients and cirrhotic patients.
| Parameters | Control Group | Chronic Hepatitis Patients | Cirrhotic Patients | ||||
|---|---|---|---|---|---|---|---|
| MM | MS+MZ | MM | MS | MZ+ZZ | MM | MS+SS | |
| Serum ALT (IU/mL) | 30.2±1.5 | 28.7±2.6 | 65.4±6.9 | 67.7±13.20 | 163.7±80.2 | 87.0±80.2 | 176.3±43.4a |
| Serum AST (IU/mL) | 30.1±1.6 | 31.0±2.5 | 68.0±5.6 | 57.3±10.50 | 139.0±47.9bc | 127.7±20.1 | 300.7±65.9a |
| Serum ALP (IU/mL) | 44.5±1.9 | 38.7±0.9 | 109.3±7.4 | 115.5±5.70 | 122.0±34.5 | 114.6±10.8 | 130.7±34.8 |
| Total bilirubin (mg/dL) | 0.8±0.1 | 0.7±0.2 | 0.8±0.07 | 0.9±0.10 | 1.3±0.5 | 0.9±0.1 | 1.8±0.4a |
| Direct bilirubin (mg/dL) | 0.2±0.02 | 0.1±0.03 | 0.2±0.02 | 0.2±0.04 | 0.5±0.3 | 0.2±0.01 | 0.5±0.2a |
| Albumin (g/dL) | 3.8±0.05 | 3.9±0.2 | 3.7±0.1 | 3.7±0.10 | 3.6±0.03 | 3.3±0.1 | 2.7±0.1a |
| Prothrombin time (seconds) | 11.2±0.2 | 11.3±0.3 | 11.5±0.2 | 11.2±0.20 | 12.3±0.9 | 13.7±0.6 | 15.0±0.6 |
| AFP (ng/mL) | 6.0±0.5 | 5.0±1.0 | 8.6±0.9 | 8.7±1.00 | 9.3±1.0 | 25.6±10.3 | 48.3±11.2 |
| Fibrosis score (1-6) | — | — | 2.1±0.3 | 1.5±0.20 | 2.3±0.3 | 4.6±0.2 | 4.3±0.3 |
SE: standard error; ALT: alanine transaminase; AST: aspartate transaminase; ALP: alkaline phosphate; AFP: α fetopreotein.
a significant values (p <0.05) when the MS+SS genotypes of cirrhotic patients were compared to the MM genotypes of cirrhotic patients.
b significant values (p <0.05) when the MZ+ZZ genotypes of chronic hepatitis patients were compared to the MM genotypes of chronic hepatitis patients.
c significant values (p <0.05) when the MZ+ZZ genotypes of chronic hepatitis patients were compared to the MS genotypes of chronic hepatitis patients.
a significant values (p <0.05) when the MS+SS genotypes of cirrhotic patients were compared to the MM genotypes of cirrhotic patients.
a significant values (p <0.05) when the MS+SS genotypes of cirrhotic patients were compared to the MM genotypes of cirrhotic patients.